Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients

World Journal of Gastroenterology

Volumn 21, Issue 48, 2015, Pages 13566-13573

  Lin, Wei Chen ^a   Wong, Jau Min ^b   Tung, Chien Chih ^b   Lin, Ching Pin ^c   Chou, Jen Wei ^d   Wang, Horng Yuan ^a   Shieh, Ming Jium ^b   Chang, Chin Hao ^b   Liu, Heng Hsiu ^e   Wei, Shu Chen ^b  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Crohn's disease; Endoscopic score; Fecal calprotectin; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASIAN; COLONOSCOPY; CORRELATION COEFFICIENT; CROHN DISEASE; CROHN'S DISEASE ENDOSCOPIC INDEX OF SEVERITY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; FECES ANALYSIS; FECES LEVEL; FEMALE; GROUPS BY AGE; HUMAN; ILEOCOLONOSCOPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROCTITIS; PROSPECTIVE STUDY; REMISSION; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS; ULCERATIVE COLITIS ENDOSCOPIC INDEX OF SEVERITY; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMISTRY; COLITIS, ULCERATIVE; COLON; DRUG EFFECTS; ETHNOLOGY; FECES; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; TAIWAN; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; COLON; COLONOSCOPY; CROHN DISEASE; FECES; FEMALE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TAIWAN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84953300892     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i48.13566     Document Type: Article

References (34)

1. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, Forbes A. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-459 [PMID: 14762782 DOI: 10.1053/j.gastro.2003.11.010]
2. Best WR. Predicting the Crohn's disease activity index from the Harvey-Bradshaw Index. Inflamm Bowel Dis 2006; 12: 304-310 [PMID: 16633052 DOI: 10.1097/01.MIB.0000215091.77492.2a]
3. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-753 [PMID: 16698746 DOI: 10.1136/gut.2005.082909]
4. Andersson KB, Sletten K, Berntzen HB, Dale I, Brandtzaeg P, Jellum E, Fagerhol MK. The leucocyte L1 protein: identity with the cystic fibrosis antigen and the calcium-binding MRP-8 and MRP-14 macrophage components. Scand J Immunol 1988; 28: 241-245 [PMID: 3413449 DOI: 10.1111/j.1365-3083.1988.tb02437.x]
5. Bosco Dhas DB, Bhat BV, Gane DB. Role of Calprotectin in Infection and Inflammation. Curr Pediatr Res 2012; 16: 83-94
6. Paduchova Z, Durackova Z. Fecal calprotectin as a promising marker of inflammatory diseases. Bratisl Lek Listy 2009; 110: 598-602 [PMID: 20017448]
7. Røseth AG, Fagerhol MK, Aadland E, Schjønsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992; 27: 793-798 [PMID: 1411288 DOI: 10.3109/00365529209011186]
8. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22 [PMID: 10889150 DOI: 10.1053/gast.2000.8523]
9. Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S, Golden BE. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 33: 14-22 [PMID: 11479402 DOI: 10.109 7/00005176-200107000-00003]
10. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel, 2013. Available from: URL: http://www.nice.org.uk/guidance/dg11/resources/guidance-faecal-calprotectin-diagnostictests-for-inflammatory-diseases-of-the-bowel-pdf
11. Joshi S, Lewis SJ, Creanor S, Ayling RM. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem 2010; 47: 259-263 [PMID: 19740914 DOI: 10.1258/acb.2009.009061]
12. Liu JR, Sheng XY, Hu YQ, Yu XG, Westcott JE, Miller LV, Krebs NF, Hambidge KM. Fecal calprotectin levels are higher in rural than in urban Chinese infants and negatively associated with growth. BMC Pediatr 2012; 12: 129 [PMID: 22917269 DOI: 10.1186/1471-2431-12-129]
13. D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, Geens P, Iwens D, Aerden I, Van Assche G, Van Olmen G, Rutgeerts P. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2218-2224 [PMID: 22344983 DOI: 10.1002/ibd.22917]
14. Aomatsu T, Yoden A, Matsumoto K, Kimura E, Inoue K, Andoh A, Tamai H. Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig Dis Sci 2011; 56: 2372-2377 [PMID: 21394462 DOI: 10.1007/s10620-011-1633-y]
15. Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K. Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn's disease after ileocolonic resection: A prospective pilot study. United European Gastroenterol J 2013; 1: 368-374 [PMID: 24917985 DOI: 10.1177/2050640613501818]
16. Xiang JY, Ouyang Q, Li GD, Xiao NP. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol 2008; 14: 53-57 [PMID: 18176961 DOI: 10.3748/wjg.14.53]
17. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989; 30: 983-989 [PMID: 2668130 DOI: 10.1136/gut.30.7.983]
18. Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lémann M, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Bernhardt CA, Mary JY, Sandborn WJ. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012; 61: 535-542 [PMID: 21997563 DOI: 10.1136/gutjnl-2011-300486]
19. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012; 61: 1619-1635 [PMID: 22842618 DOI: 10.1136/gutjnl-2012-302830]
20. Theede K, Holck S, Ibsen P, Ladelund S, Nordgaard-Lassen I, Nielsen AM. Level of Fecal Calprotectin Correlates With Endoscopic and Histologic Inflammation and Identifies Patients With Mucosal Healing in Ulcerative Colitis. Clin Gastroenterol Hepatol 2015; 13: 1929-1936.e1 [PMID: 26051392 DOI: 10.1016/j.cgh.2015.05.038]
21. Limburg PJ, Ahlquist DA, Sandborn WJ, Mahoney DW, Devens ME, Harrington JJ, Zinsmeister AR. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol 2000; 95: 2831-2837 [PMID: 11051356 DOI: 10.1016/S0002-9270(00)01987-0]
22. Gallo A, Gasbarrini A, Passaro G, Landolfi R, Montalto M. Role of fecal calprotectin in monitoring response to therapy in inflammatory bowel diseases. J Clin Cell Immunol 2014; 5: 252 [DOI: 10.4172/2 155-9899.1000252]
23. Schoepfer AM, Lewis JD. Serial fecal calprotectin measurements to detect endoscopic recurrence in postoperative Crohn's disease: is colonoscopic surveillance no longer needed?Gastroenterology 2015; 148: 889-892 [PMID: 25805423 DOI: 10.1053/j.gastro.2015.03.022]
24. Holmquist L, Ahrén C, Fällström SP. Clinical disease activity and inflammatory activity in the rectum in relation to mucosal inflammation assessed by colonoscopy. A study of children and adolescents with chronic inflammatory bowel disease. Acta Paediatr Scand 1990; 79: 527-534 [PMID: 2386043 DOI: 10.1111/j.1651-2227.1990.tb11507.x]
25. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009; 15: 1851-1858 [PMID: 19462421 DOI: 10.1002/ibd.20986]
26. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, Seibold F. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105: 162-169 [PMID: 19755969 DOI: 10.1038/ajg.2009.545]
27. D'Incà R, Dal Pont E, Di Leo V, Ferronato A, Fries W, Vettorato MG, Martines D, Sturniolo GC. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007; 22: 429-437 [PMID: 16838143 DOI: 10.1007/s00384-006-0159-9]
28. Hanai H, Takeuchi K, Iida T, Kashiwagi N, Saniabadi AR, Matsushita I, Sato Y, Kasuga N, Nakamura T. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig Dis Sci 2004; 49: 1438-1443 [PMID: 15481316 DOI: 10.1023/B: DDAS.0 000042243.47279.87]
29. Sipponen T, Savilahti E, Kärkkäinen P, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008; 14: 1392-1398 [PMID: 18484671 DOI: 10.1002/ibd.20490]
30. D'Incà R, Dal Pont E, Di Leo V, Benazzato L, Martinato M, Lamboglia F, Oliva L, Sturniolo GC. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 2008; 103: 2007-2014 [PMID: 18802997 DOI: 10.1111/j.1572-0241.2008.01870.x]
31. Schoepfer AM, Beglinger C, Straumann A, Safroneeva E, Romero Y, Armstrong D, Schmidt C, Trummler M, Pittet V, Vavricka SR. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis 2013; 19: 332-341 [PMID: 23328771 DOI: 10.1097/MIB.0b013e3182810066]
32. Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, Ricchiuti A, Marchi S, Bottai M. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005; 54: 364-368 [PMID: 15710984 DOI: 10.1136/gut.2004.043406]
33. Saverymuttu SH, Hodgson HJ, Chadwick VS, Pepys MB. Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut 1986; 27: 809-813 [PMID: 3732890 DOI: 10.1136/gut.27.7.809]
34. Gecse KB, Brandse JF, van Wilpe S, Löwenberg M, Ponsioen C, van den Brink G, D'Haens G. Impact of disease location on fecal calprotectin levels in Crohn's disease. Scand J Gastroenterol 2015; 50: 841-847 [PMID: 25636819 DOI: 10.3109/00365521.2015.1008 035]